Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.32 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 3/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125903 | 0.89 | NAMPT (0.38) | LIPGLIPCPIP4K2APIP4K2CIDH2 | |
| SCHEMBL4117665 | 0.88 | LIPG (0.34) | LIPGLIPCPIP4K2APIP4K2CIDH2 | |
| SCHEMBL4125700 | 0.86 | ALDH1A1 (0.38) | — | |
| SCHEMBL4132234 | 0.84 | ATM (0.38) | LIPGLIPCPIP4K2APIP4K2CEDNRA | |
| SCHEMBL4117748 | 0.84 | LIPG (0.32) | LIPGLIPCPIP4K2APIP4K2CIDH2 | |
| SCHEMBL4125605 | 0.84 | LIPG (0.33) | LIPGLIPCPIP4K2APIP4K2CBRAF | |
| SCHEMBL4127371 | 0.84 | MAOA (0.35) | LIPGLIPCIDH2 | |
| SCHEMBL4125873 | 0.84 | CYP1A2 (0.33) | LIPGLIPCPIP4K2APIP4K2CIDH2 | |
| SCHEMBL4126636 | 0.84 | GAA (0.39) | PIP4K2APIP4K2C | |
| SCHEMBL4120137 | 0.83 | LIPG (0.32) | LIPGLIPCPIP4K2APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | LIPG 2467/4885LIPC 83/4885PIP4K2A 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.